The Influence of Bisphosphonates on Viability, Migration, and Apoptosis of Human Oral Keratinocytes--in Vitro Study

Overview

Journal Clin Oral Investig

Specialty Dentistry

Date 2011 Jan 13

PMID 21225298

Citations 54

Authors

Andreas M Pabst

Thomas Ziebart

Felix P Koch

Katherine Y Taylor

Bilal Al-Nawas

Christian Walter

Affiliations

Soon will be listed here.

Abstract

Bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ) is one of the most often seen side effects in patients treated with bisphosphonates, presenting clinically as a non-healing wound. One theory of BP-ONJ etiology describes a negative effect on soft tissues, especially on keratinocytes, which play an important role in oral wound healing and oral soft tissue regeneration. A high cell viability of keratinocytes, which can migrate to the affected location, is essential for wound healing. The aim of this in vitro study was to investigate the effect of differently potent bisphosphonates on human oral keratinocytes (HOK).Three nitrogen-containing bisphosphonates (ibandronate, pamidronate, and zoledronate) and one non-nitrogen-containing bisphosphonate (clodronate) were compared concerning their potency on cell viability (calcein assay and MTT assay), migration ability (Boyden chamber migration assay and scratch wound proliferation assay), and apoptosis (TUNEL assay) of HOK.The nitrogen-containing bisphosphonates, particularly highly potent pamidronate and zoledronate preparations, had a strong negative influence on cell viability, migration ability, and apoptosis of HOK. The non-nitrogen-containing clodronate even increased cell viability in higher concentrations.This study demonstrates that bisphosphonates have a strong influence on HOK on different cellular levels like cell viability, migration ability, and apoptosis rate. The results support the theory that BP-ONJ is a multifactorially caused disease.Furthermore, this in vitro study confirms the theory that perioperative interruption of bisphosphonate application during dental surgical procedures might be feasible to promote better tissue regeneration and wound healing.

Citing Articles

Bisphosphonate- and disumab-related gingival disorders: case analysis from the U.S. Food and Drug Administration Adverse Event Reporting System.

Wang L, Zhang W, Zhao C, Fu Z Front Endocrinol (Lausanne). 2024; 15:1367607.

PMID: 39239094 PMC: 11374645. DOI: 10.3389/fendo.2024.1367607.

Inflammation Can Be a High-Risk Factor for Mucosal Nonunion of MRONJ by Regulating SIRT1 Signaling When Treated with an Oncologic Dose of Zoledronate.

Zhu S, Cui Y, Zhang W, Ji Y, Li L, Luo S Drug Des Devel Ther. 2024; 18:2793-2812.

PMID: 38979400 PMC: 11229984. DOI: 10.2147/DDDT.S456811.

Osteonecrosis of the Jaw Associated with Bisphosphonates Infusion for Treatment of Plasma Cell Myeloma-A Retrospective Observational Study of Northern Portuguese Population.

Ferreira S, Amaral J, Pacheco J, Salazar F, Monteiro L J Clin Med. 2024; 13(9).

PMID: 38731207 PMC: 11084472. DOI: 10.3390/jcm13092679.

The effect of antiresorptive therapy on the prevalence and severity of oral lichen planus: a retrospective study.

Parvini P, Obreja K, Cafferata E, Aini T, Lermen Y, Begic A BMC Oral Health. 2024; 24(1):547.

PMID: 38730315 PMC: 11088150. DOI: 10.1186/s12903-024-04331-5.

Etiopathogenesis of medication-related osteonecrosis of the jaws: a review.

Bassan Marinho Maciel G, Maciel R, Linhares Ferrazzo K, Cademartori Danesi C J Mol Med (Berl). 2024; 102(3):353-364.

PMID: 38302741 DOI: 10.1007/s00109-024-02425-9.

References

Carano A, Teitelbaum S, Konsek J, Schlesinger P, Blair H . Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 1990; 85(2):456-61. PMC: 296445. DOI: 10.1172/JCI114459. View

Marx R, Cillo Jr J, Ulloa J . Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65(12):2397-410. DOI: 10.1016/j.joms.2007.08.003. View

Walter C, Klein M, Pabst A, Al-Nawas B, Duschner H, Ziebart T . Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig. 2009; 14(1):35-41. DOI: 10.1007/s00784-009-0266-4. View

Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B . Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis. 2010; 17(2):194-9. DOI: 10.1111/j.1601-0825.2010.01720.x. View

Walter C, Al-Nawas B, Grotz K, Thomas C, Thuroff J, Zinser V . Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol. 2008; 54(5):1066-72. DOI: 10.1016/j.eururo.2008.06.070. View

Diel I, Bergner R, Grotz K . Adverse effects of bisphosphonates: current issues. J Support Oncol. 2008; 5(10):475-82. View

Felix R, Guenther H, Fleisch H . The subcellular distribution of [14C]dichloromethylenebisphosphonate and [14C]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int. 1984; 36(1):108-13. DOI: 10.1007/BF02405302. View

Scheper M, Chaisuparat R, Cullen K, Meiller T . A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. Fibrogenesis Tissue Repair. 2010; 3:6. PMC: 2859744. DOI: 10.1186/1755-1536-3-6. View

Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S . Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002; 42(11):1228-36. DOI: 10.1177/009127002762491316. View

10.

Ruggiero S, Dodson T, Assael L, Landesberg R, Marx R, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009; 67(5 Suppl):2-12. DOI: 10.1016/j.joms.2009.01.009. View

11.

Neville-Webbe H, Coleman R . Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer. 2010; 46(7):1211-22. DOI: 10.1016/j.ejca.2010.02.041. View

12.

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

13.

Reid I, Bolland M, Grey A . Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone. 2007; 41(3):318-20. DOI: 10.1016/j.bone.2007.04.196. View

14.

Walker K, Olson M . Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev. 2005; 15(1):62-8. DOI: 10.1016/j.gde.2004.11.001. View

15.

Gonzalez-Moles M, Bagan-Sebastian J . Alendronate-related oral mucosa ulcerations. J Oral Pathol Med. 2000; 29(10):514-8. DOI: 10.1034/j.1600-0714.2000.291006.x. View

16.

Walter C, Grotz K, Kunkel M, Al-Nawas B . Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer. 2006; 15(2):197-202. DOI: 10.1007/s00520-006-0120-z. View

17.

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

18.

Stopeck A, Lipton A, Body J, Steger G, Tonkin K, De Boer R . Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28(35):5132-9. DOI: 10.1200/JCO.2010.29.7101. View

19.

Suri S, Monkkonen J, Taskinen M, Pesonen J, Blank M, Phipps R . Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone. 2001; 29(4):336-43. DOI: 10.1016/s8756-3282(01)00589-0. View

20.

Fromigue O, Body J . Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest. 2002; 25(6):539-46. DOI: 10.1007/BF03345497. View